A Study to Evaluate the Safety and Pharmacokinetics of RC001 in Children With Dravet Syndrome

Early Phase 1RecruitingNCT07675746

Second Affiliated Hospital of Guangzhou Medical University8 enrolled

Overview

This is an open-label, single-center study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of intrathecal RC001 in patients with Dravet syndrome aged 2 to 18 years. The study includes a dose-escalation part followed by a fixed dose treatment part, with participant progression based on investigator-assessed safety and efficacy.

This is an open-label, single-center clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of RC001 administered intrathecally in patients aged 2 to 18 years with Dravet syndrome. The study consists of two stages: Stage 1 (intra-subject dose escalation) and Stage 2 (fixed-dose multiple dosing). In Stage 1, three cohorts will be enrolled with a total of three participants. In Stage 2, a total of five participants will be enrolled to receive fixed-dose multiple administrations. Participants in both the dose-escalation stage and the fixed-dose multiple dosing stage may enter an extension phase after completion of the last dose, based on the investigator's assessment of efficacy and safety.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Dravet Syndrome (DS)

Interventions

RC001 injection-Dose Escalation CohortDRUG

RC001 will be administered using a sequential dose-escalation scheme. Participants will receive ascending dose levels of RC001 according to the study protocol. Dose escalation will proceed only after safety data from prior participants have been reviewed and deemed acceptable. This intervention is intended to evaluate safety, tolerability, and preliminary pharmacodynamic effects at increasing dose levels.

RC001 injection-Fixed Dose CohortDRUG

RC001 will be administered at a predefined fixed dose level selected based on safety, tolerability, and pharmacological data obtained from the dose-escalation cohort. This intervention is intended to further evaluate safety and preliminary efficacy at the selected dose level in a fixed-dose setting.

Eligibility

Sex: ALLMin age: 2 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients aged 2-18 years with Dravet syndrome caused by SCN1A mutations, with onset before 12 months of age characterized by focal seizures, hemiclonic seizures, generalized tonic-clonic seizures, or myoclonic seizures, and with MRI excluding progressive neurological disease either historically or at screening. Enrolled participants will be assigned as follows: 1 participant aged 13-18 years, 1 aged 7-12 years, and 1 aged 2-6 years will undergo intra-subject dose escalation; 5 participants aged 2-12 years will receive fixed-dose multiple administrations. 2. Seizure frequency requirements: at least 6 cumulative seizures within 12 weeks prior to the day of signing the ICF, and at least 2 seizures within 4 weeks prior to ICF signing. For participants in Stage 2 (fixed-dose multiple administration), seizure frequency must also be ≥4 within 4 weeks after ICF signing. 3. Documented pathogenic or likely pathogenic variants in the SCN1A gene associated with Dravet syndrome. 4. Prior treatment with at least one anti-epileptic intervention, including anti-seizure medications (ASM), ketogenic diet, or vagus nerve stimulation (VNS), with inadequate seizure control or discontinuation due to adverse events (AEs). 5. Use of at least one ASM prior to screening, with a stable dose for at least 4 weeks before screening. 6. All epilepsy-related treatments, including ASM and other interventions (ketogenic diet and VNS), must be stable for at least 4 weeks prior to screening and are expected to remain stable throughout the study (medications adjusted by body weight are allowed). 7. Willingness to participate and provision of written informed consent. Exclusion Criteria: 1. Presence of other known pathogenic gene mutations causing Dravet syndrome, or SCN1A gain-of-function mutations reported in the literature and/or experimentally validated, including but not limited to: Ala23Glu, Thr162Ile, Thr226Met, Ser228Pro, Val229Leu, Ile236Val, Ile236Thr, Val250Leu, Leu263Val, Thr398Met, Ala420Val, Val422Leu, Ile883Thr, Leu893Phe, Ala989Thr, Thr1174Ser, Trp1204Arg, Ala1339Asp, Pro1345Ser, Pro1345Leu, Ser1346Pro, Ile1347Val, Val1481Ile, Ile1483Met, Gln1489Lys, Ile1498Thr, Ile1498Met, Phe1499Leu, Met1500Val, Arg1575Cys, Val1611Phe, Leu1624Pro, Arg1636Gln, Arg1648Cys, Leu1649Gln, Leu1660Ile, Phe1661Leu, Ala1669Glu, Leu1670Trp, Gly1674Arg, Phe1774Ser, Asp1866Tyr. 2. Current maintenance treatment with anti-epileptic drugs primarily acting as sodium channel blockers, including but not limited to carbamazepine, oxcarbazepine, lamotrigine, lacosamide, or rufinamide. 3. Ongoing neuromodulation therapy (e.g., responsive neurostimulation or deep brain stimulation), excluding vagus nerve stimulation (VNS). 4. Receipt of gene therapy or cell therapy within 1 year prior to screening. 5. Receipt of any vaccination within 12 weeks prior to screening. 6. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2× the upper limit of normal (ULN), or total bilirubin \>1.5× ULN; renal insufficiency or serum creatinine \>1.2× ULN. 7. Presence of any severe uncontrolled disease other than Dravet syndrome. 8. History of autoimmune disease, or uncontrolled infectious disease within 1 week prior to screening. 9. History of brain or spinal cord disease (other than epilepsy, Dravet syndrome, or trauma), or history of bacterial meningitis. 10. Spinal deformity or other conditions that may interfere with normal cerebrospinal fluid (CSF) flow, or implantation of a CSF shunt. 11. Pregnant or breastfeeding females. 12. Any other significant disease or condition that, in the investigator's judgment, may pose a risk to the patient, interfere with study results, or affect the patient's ability to participate in the study.

Locations (1)

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

RECRUITING

Outcomes

Primary Outcomes

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

A treatment-emergent adverse event is defined as any adverse event that occurs or worsens after the first dose of RC001 through the end of follow-up. TEAEs will be summarized by system organ class, preferred term, severity, seriousness, and relationship to study drug or study procedure.

Time frame: From first dose to 24 weeks after the last dose

Number of Participants With Serious Adverse Events (SAEs)

Serious adverse events will be collected and summarized throughout the study.

Time frame: From signing informed consent to 24 weeks after the last dose

Number of Participants With Clinically Significant Abnormalities in Vital Signs

Vital signs include body temperature, heart rate, respiratory rate, systolic blood pressure, and diastolic blood pressure. Clinically significant abnormalities will be determined by the investigator.

Time frame: From baseline to 24 weeks after the last dose

Number of Participants With Clinically Significant Abnormal Physical Examination Findings

Physical examination findings will be assessed for clinically significant abnormalities as determined by the investigator.

Time frame: From baseline to 24 weeks after the last dose

Number of Participants With Clinically Significant Abnormal Laboratory Test Results

Laboratory assessments may include hematology, serum chemistry, coagulation, urinalysis, and cerebrospinal fluid laboratory tests, as applicable. Clinically significant abnormalities will be determined by the investigator.

Time frame: From baseline to 24 weeks after the last dose

Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings

ECG parameters may include heart rate, PR interval, QRS duration, QT interval, and corrected QT interval. Clinically significant abnormalities will be determined by the investigator.

Central Contacts

Weiping Liao, Ph.D

CONTACT

086-020-34152498 wpliao@163.net

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Maximum Observed Plasma Concentration (Cmax) of RC001

Cmax of RC001 in plasma following intrathecal administration.

Time frame: From first dose to last dose up to 12 weeks

Time to Maximum Observed Plasma Concentration (Tmax) of RC001

Tmax of RC001 in plasma following intrathecal administration.

Time frame: From first dose through 12 weeks

Trough Concentration (Ctrough) of RC001 in Cerebrospinal Fluid

Trough concentration of RC001 in cerebrospinal fluid before each intrathecal dose.

Time frame: Prior to each dose through 12 weeks

Percentage Change From Baseline in Countable Seizure Frequency at 12 Weeks After the Last Dose

Countable seizure frequency will be calculated as the number of countable seizures during the 28-day period preceding 12 weeks after the last dose of RC001.Baseline countable seizure frequency is defined as the number of countable seizures during baseline observation period. Percentage change from baseline will be calculated as: (post-baseline 28-day seizure frequency - baseline 28-day seizure frequency) / baseline 28-day seizure frequency x 100%.

Time frame: Baseline and the 28-day period preceding 12 weeks after the last dose

Percentage Change From Baseline in Countable Seizure Frequency at 24 Weeks After the Last Dose

Countable seizure frequency will be calculated as the number of countable seizures during the 28-day period preceding 24 weeks after the last dose of RC001. Baseline countable seizure frequency is defined as the number of countable seizures during baseline observation period. Percentage change from baseline will be calculated as: (post-baseline 28-day seizure frequency - baseline 28-day seizure frequency) / baseline 28-day seizure frequency x 100%.

Time frame: Baseline and the 28-day period preceding 24 weeks after the last dose

Clinical Global Impression of Change (CGI-C) Score at 24 Weeks After the Last Dose

The Clinical Global Impression of Change (CGI-C) is a clinician-rated 7-point scale assessing overall clinical change relative to baseline. Scores range from 1 to 7: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Lower scores indicate greater improvement.

Time frame: 24 weeks after the last dose

Caregiver Global Impression of Change (CaGI-C) Score at 24 Weeks After the Last Dose

The Caregiver Global Impression of Change (CaGI-C) is a caregiver-rated 7-point scale assessing overall clinical change relative to baseline. Scores range from 1 to 7: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Lower scores indicate greater improvement.

Time frame: 24 weeks after the last dose

Change From Baseline in Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) Expressive Communication Raw Score at 24 Weeks After the Last Dose

The Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) measures adaptive behavior. The Expressive Communication subdomain raw score will be assessed. Raw scores have a minimum value of 0, and the maximum value varies by subdomain according to the Vineland-3 scoring manual. Higher scores indicate better adaptive functioning.

Time frame: Baseline and 24 weeks after the last dose

Change From Baseline in Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) Receptive Communication Raw Score at 24 Weeks After the Last Dose

The Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) measures adaptive behavior. The Receptive Communication subdomain raw score will be assessed. Raw scores have a minimum value of 0, and the maximum value varies by subdomain according to the Vineland-3 scoring manual. Higher scores indicate better adaptive functioning.

Time frame: Baseline and 24 weeks after the last dose

Change From Baseline in Age-Appropriate Wechsler Intelligence Scale Score at 24 Weeks After the Last Dose

Cognitive function will be assessed using an age-appropriate Wechsler intelligence scale. The selected composite or total score will be analyzed as the change from baseline. Higher scores indicate better cognitive functioning. The applicable scale version and score range will be defined according to the participant's age and the study assessment manual.

Time frame: Baseline and 24 weeks after the last dose